We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

By HospiMedica International staff writers
Posted on 25 Sep 2026

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. More...

Troponin testing helps assess heart muscle damage, but it is usually performed in a hospital laboratory after arrival. Earlier risk assessment could help ambulance crews decide who needs emergency evaluation. A new study shows how point-of-care troponin testing combined with a clinical risk score changed prehospital triage in the Netherlands.

The study, conducted by the Rotterdam-Rijnmond ambulance service, evaluated a triage approach combining a QuidelOrtho high-sensitivity point-of-care troponin test with the HEART score. The blood test measures troponin proteins, which rise when heart muscle is damaged, and can provide results in less than 20 minutes. The HEART score then incorporates the troponin result with medical history, electrocardiogram findings, age, and other risk factors to estimate the likelihood of a major adverse cardiovascular event.

The before-and-after study enrolled 1,022 patients with chest pain between 2022 and 2025. During the before phase, 539 patients received the usual ambulance assessment, while in the after phase, 483 patients were additionally evaluated using the point-of-care troponin test and HEART score. Patients with a low HEART score and a troponin level below four nanograms per liter could remain at home or be referred to a general practitioner, provided ambulance crews did not suspect another serious condition. Follow-up lasted at least one month for all patients and exceeded six months for most.

Under usual care, 19 patients (3.5%) were left at home, compared with 165 patients (34.2%) after the new approach was introduced. With follow-up data available for 86% of participants, 109 patients (12.4%) experienced a major adverse cardiovascular event within 30 days, including 15.0% in the before phase and 9.8% in the after phase. Among patients who remained at home, one of 165 (0.6%) experienced such an event after implementation of the new approach, compared with none of the 19 patients left at home under usual care.

The researchers noted that not all eligible patients were included and that the after-phase group contained a higher proportion of low-risk patients, although adjusting for this difference did not meaningfully alter the results. Overall, the study suggests that combining point-of-care troponin testing with HEART scoring may help reduce emergency department referrals among selected patients with chest pain.

"Hospital referrals were reduced significantly, avoiding hospital overcrowding and unnecessary use of medical resources, while enabling more patients to avoid the stresses of the hospital environment. This is good for patients and good for hospitals," said Dr. Barbra Backus, a co-developer of the HEART score, while presenting the findings at the European Emergency Medicine Congress.

"Beyond emergency medical services, this approach could, with further validation, eventually be extended to other primary care settings, facilitating more efficient patient triage and resource utilization across the health care system," said Dr. Maša Sorić, head of the emergency department at University Hospital Merkur in Zagreb, Croatia, and a member of the EUSEM abstract selection committee.

Related Links
European Society for Emergency Medicine


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: The tool analyzes 3D time-of-flight MR angiography to measure brain vessel length, radius, volume, branching, tortuosity, and other structural features. (Photo courtesy of University of Rochester Medical Center)

MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.